PSB202, an engineered bi-specific molecule consisting of an Fc-enhanced humanized type II anti-CD20 IgG1 and a humanized anti-CD37 IgG1, is currently under evaluation in a phase I clinical trial against indolent/relapsed CLL (ClinicalTrials.gov Identifier: NCT05003141). The gene discussed is CD37; the disease is B-cell chronic lymphocytic leukemia.